Belatacept reduces skin cancer risk in kidney transplant recipients
Author:
Publisher
Elsevier BV
Subject
Dermatology
Reference5 articles.
1. Skin cancers in organ transplant recipients;Mittal;Am J Transplant,2017
2. Safety and efficacy outcomes 3 years after switching to belatacept from a calcineurin inhibitor in kidney transplant recipients: results from a phase 2 randomized trial;Grinyo;Am J Kidney Dis,2017
3. Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study;Durrbach;Am J Transplant,2016
4. Cyclosporine induces cancer progression by a cell-autonomous mechanism;Hojo;Nature,1999
5. Opposing roles for calcineurin and ATF3 in squamous skin cancer;Wu;Nature,2010
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cutaneous Squamous Cell Carcinoma in Patients with Solid-Organ-Transplant-Associated Immunosuppression;Cancers;2024-09-04
2. Belatacept based immunosuppression: What and when to combine?;Transplant Immunology;2024-08
3. De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy;Journal of the American Academy of Dermatology;2024-06
4. Skin Cancer in the Immunocompromised Patient;Rook's Textbook of Dermatology;2024-03-19
5. Updates in Skin Cancer in Transplant Recipients and Immunosuppressed Patients: Review of the 2022–2023 Scientific Symposium of the International Immunosuppression and Transplant Skin Cancer Collaborative;Transplant International;2024-03-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3